Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT06442709 2024-06-04

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Phase NA Unknown

100 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT03921671 2024-05-29

RELEVENT

Phase 2 Unknown

60 enrolled

Thoracic

Neoplasm Metastasis, Thymoma

NCT04029181 2024-05-03

ImmunoPET With an Anti-CD8 Imaging Agent

Phase 1/2 Unknown

47 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03423199 2024-03-22

PATHWAY

Phase 3 Unknown

180 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04243720 2024-03-12

IRIS

Unknown

100 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05872867 2024-03-12

MK-3475-E90

Phase 1 Unknown

54 enrolled

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Clinical Trials

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

RELEVENT

ImmunoPET With an Anti-CD8 Imaging Agent

PATHWAY

IRIS

MK-3475-E90

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

DART

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

MINI-MD

Imaging Guided Cementoplasty for Pelvic Bone Metastasis

68Ga-PSMA PET in the Prostate Cancer

68Ga-GPFAPI

HOLIPANC

PET-MaN

The Effect of Antenatal Education on Fear of Birth, Physiological Ability to Give Birth and Traumatic Birth Perception

CELEBRATE

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

LoMP

Clinical Study of SM3321 With Solid Tumors

CRLM-Z

Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases

ALPS

BIO-META

V-CHANCE

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

CartDiagPROST

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

MSCs for the Treatment of Burn Wounds

TWICE-IRI

Minnelide 101

EPOST MBC

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)

Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors

Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients

Comparison Between LDCT With DL Recontruction and Standard Dose CT

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

T1 Squamous Cell Carcinomas of the Lip

Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

HLX301

RAPASS

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Fibroblast Activation Protein Inhibitor PET/CT Imaging in Malignant Tumor of Digestive System